Intake of Korean red ginseng extract and saponin enhances the protection conferred by vaccination with inactivated influenza A virus

Journal of Ginseng Research

Volumn 36, Issue 4, 2012, Pages 396-402

  Xu, Mei Ling ^a   Kim, Hyoung Jin ^a   Choi, Yoo Ri ^a   Kim, Hong Jin ^a  

^a Chung Ang University   (South Korea)

Author keywords

Influenza a virus; Korean red ginseng; Panax ginseng; Saponin

Indexed keywords

EID: 84867687223     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.5142/jgr.2012.36.4.396     Document Type: Article

References (37)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-344.
2. Wee JJ, Park MK, Chung AS. Biological activities of ginseng and its application to human health. In: Benzie IF, Wachtel-Galor S, eds. Herbal medicine: biomolecular and clinical aspects. 2nd ed. Boca Raton: CRC Press, 2011. p. 157-174.
3. Kim SK, Park JH. Trends in ginseng research in 2010. J Ginseng Res 2011;35:389-398.
4. Ernst E. Panax ginseng: An overview of the clinical evidence. J Ginseng Res 2010;34:259-263.
5. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009;7:293-302.
6. Kim JY, Kim HY, Kim HJ. Effect of oral administration of Korean red ginseng on influenza A (H1N1) virus infection. J Ginseng Res 2011;35:104-110.
7. Nah SY. Ginseng: recent advances and trends. Korean J Ginseng Sci 1997;21:1-12.
8. Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 2009;27:1787-1796.
9. Jie YH, Cammisuli S, Baggiolini M. Immunomodula-tory effects of Panax ginseng C.A. Meyer in the mouse. Agents Actions 1984;15:386-391.
10. Rivera E, Daggfeldt A, Hu S. Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. Vet Immunol Immunopathol 2003;91:19-27.
11. Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 2006;40:53-59.
12. Roxas M, Jurenka J. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Altern Med Rev 2007;12:25-48.
13. World Health Organization. Influenza (seasonal): fact sheet no. 211. Available from: http://www.who.int/media-centre/factsheets/fs211/en/index.html.
14. Nichol KL. Improving influenza vaccination rates among adults. Cleve Clin J Med 2006;73:1009-1015.
15. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-138.
16. Centers for Disease Control and Prevention. Fluvaccine effectiveness: questions and answers for health professionals. Available from: http://www.cdc.gov/flu/profes-sionals/vaccination/effectivenessqa.htm.
17. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159-1169.
18. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza: United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010;59:1057-1062.
19. Foster SL, Moore WP. High-dose influenza vaccination in the elderly. J Am Pharm Assoc (2003) 2010;50:546-547.
20. Herrera GA, Iwane MK, Cortese M, Brown C, Gershman K, Shupe A, Averhoff F, Chaves SS, Gargiullo P, Bridges CB. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vaccine 2007;25:154-160.
21. Hu S, Concha C, Lin F, Persson Waller K. Adjuvant effect of ginseng extracts on the immune responses to immunisation against Staphylococcus aureus in dairy cattle. Vet Immunol Immunopathol 2003;91:29-37.
22. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-497.
23. Xu L, Bao L, Lv Q, Deng W, Ma Y, Li F, Zhan L, Zhu H, Ma C, Qin C. A single-amino-acid substitution in the HA protein changes the replication and pathogenicity of the 2009 pandemic A (H1N1) influenza viruses in vitro and in vivo. Virol J 2010;7:325.
24. Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 2008;380:412-420.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
26. Prabakaran M, Madhan S, Prabhu N, Geng GY, New R, Kwang J. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res 2010;86:180-187.
27. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Pa-lese P. Cellular proteins in influenza virus particles. PLoS Pathog 2008;4:e1000085.
28. Song X, Hu S. Adjuvant activities of saponins from traditional Chinese medicinal herbs. Vaccine 2009;27:4883-4890.
29. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Oster-haus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984;308:457-460.
30. Wu CA, Yang YW. Induction of cell death by saponin and antigen delivery. Pharm Res 2004;21:271-277.
31. Rajput ZI, Hu SH, Xiao CW, Arijo AG. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 2007;8:153-161.
32. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DR, Macdonald GH, McCullers JA. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 2006;13:981-990.
33. Yasui H, Kiyoshima J, Hori T, Shida K. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol 1999;6:186-192.
34. Mbawuike IN, Zhang Y, Couch RB. Control of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytes. Respir Res 2007;8:44.
35. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-969.
36. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
37. Chen WH, Toapanta FR, Shirey KA, Zhang L, Giannelou A, Page C, Frieman MB, Vogel SN, Cross AS. Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenza. Immunol Lett 2012;141:227-234.